Y.-A. Kim et al. / Tetrahedron 59 (2003) 2921–2928
2927
gel (CH2Cl2/MeOH, 5:1!1:3!0:1) gave 0.520 g (97%) of
product 2 as an white solid: Rf 0.21 (CH2Cl2/MeOH/H2O,
2:1:0.2); 1H NMR (250 MHz, CD3OD) d 0.90 (m, 3H), 1.28
(m, 24H), 1.60 (m, 2H), 2.35 (t, J¼7.4 Hz, 2H), 3.23 (s, 9H),
3.65 (m, 2H), 3.89 (m, 2H), 3.97 (m, 1H), 4.14 (m, 2H), 4.30
(m, 2H); 13C NMR (63 MHz, CD3OD) d 14.8, 24.0, 26.3,
30.5, 30.8, 30.9, 31.1, 33.4, 35.2, 35.4, 55.0, 60.7 (d,
Jcp¼4.4 Hz), 66.5, 67.7, 68.1 (d, Jcp¼5.0 Hz), 70.1 (d,
Jcp¼7.6 Hz), 175.6; FTIR (KBr, cm21) 3242, 2918, 2851,
1736, 1468, 1241, 1092, 970; FABHRMS [MþH]þ m/z
calcd for C24H51NO7P 496.3403, found 496.3401.
3.1.10. 1-Benzyl-3-palmitoyl-rac-glycero-2-phospho-
choline (11). Compound 11 was prepared under the
procedure outlined above for compound 8 and was obtained
as a white solid (0.189 g, 46%): Rf 0.31 (CH2Cl2/MeOH/H2-
1
O, 2:1:0.2); H NMR (250 MHz, CD3OD) d 0.90 (m, 3H),
1.28 (m, 24H), 1.57 (m, 2H), 2.30 (t, J¼7.4 Hz, 2H), 3.14 (s,
9H), 3.50 (m, 2H), 3.68 (d, J¼5.2 Hz, 2H), 4.24 (m, 2H),
4.30 (m, 2H), 4.48 (m, 1H), 4.55 (s, 2H), 7.32 (m, 5H); 13C
NMR (63 MHz, CD3OD) d 14.7, 24.0, 26.3, 30.5, 30.7,
30.7, 30.9, 31.1, 33.4, 35.2, 55.0, 60.7 (d, Jcp¼5.0 Hz), 65.1
(d, Jcp¼5.0 Hz), 67.6, 71.3 (d, Jcp¼5.3 Hz), 74.2 (d,
Jcp¼5.5 Hz), 74.7, 129.1, 129.4, 129.8, 139.9, 175.4;
FTIR (KBr, cm21) 3423, 2924, 2853, 1735, 1458, 1233,
1088, 969, 749; FABHRMS [MþH]þ m/z calcd for
C31H57NO7P 586.3872, found 586.3873.
3.1.7. 1-tert-Butyldiphenylsilyl-2-palmitoyl-rac-glycerol
(9). To a solution of compound 6 (0.540 g, 1.85 mmol) in
DMF (20 mL) was added imidazole (0.300 g, 4.07 mmol)
and tert-butyldiphenylsilylchloride (0.5 mL, 2.04 mmol) at
08C, and the mixture was stirred for 15 min. Then it was
diluted with ether and washed with 5% HCl, brine and dried
over Na2SO4. After evaporation of the solvent, the residue
was purified by flash column chromatography on silica gel
(n-hexane/EtOAc, 14:1!12:1) to give gave 0.300 g (70%)
of product 9 as a colorless oil: Rf 0.39 (n-hexane/EtOAc,
5:1); 1H NMR (250 MHz, CDCl3) d 0.87 (m, 3H), 1.06 (m,
9H), 1.26 (m, 24H), 1.60 (m, 2H), 2.31 (m, 3H), 3.82 (m,
4H), 4.99 (m, 1H), 7.39 (m, 6H), 7.67 (m, 4H); 13C NMR
(63 MHz, CDCl3) d 14.1, 19.1, 22.7, 24.9, 26.7, 29.1, 29.2,
29.3, 29.4, 29.6, 29.7, 31.9, 34.3, 62.5, 63.0, 74.5, 127.7,
129.8, 132.9, 135.5, 173.7; FTIR (KBr, cm21) 3651, 2927,
2856, 1737, 1428, 1112, 740; FABHRMS [MþH]þ m/z
calcd for C35H57O4Si 569.4026, found 569.4028.
3.1.11. 1-Lyso-3-palmitoyl-rac-glycero-2-phospho-
choline (3). Compound 3 was prepared under the procedure
outlined above for compound 2 and was obtained as a white
solid (0.120 g, 90%): Rf 0.21 (CH2Cl2/MeOH/H2O,
1
2:1:0.2); H NMR (250 MHz, CD3OD) d 0.88 (m, 3H),
1.29 (m, 24H), 1.61 (m, 2H), 2.35 (t, J¼7.3 Hz, 2H), 3.23 (s,
9H), 3.66 (m, 2H), 3.70 (m, 2H), 4.26 (m, 2H), 4.31 (m, 3H);
13C NMR (63 MHz, CD3OD) d 14.8, 24.0, 26.3, 30.5, 30.7,
30.9, 31.1, 33.4, 35.2, 55.0, 60.8 (d, Jcp¼5.0 Hz), 63.3 (d,
Jcp¼4.4 Hz), 64.9 (d, Jcp¼5.0 Hz), 67.8, 76.1 (d,
Jcp¼6.3 Hz), 175.4; FTIR (KBr, cm21) 3400, 2921, 2844,
1736, 1463, 1227, 1065, 949; FABHRMS [MþH]þ m/z
calcd for C24H51NO7P 496.3403, found 496.3414.
3.1.8. 1-tert-Butyldiphenylsilyl-2-palmitoyl-rac-glycero-
3-phosphocholine (10). Compound 10 was prepared
under the procedure outlined above for compound 8 and
was obtained as a white solid (0.402 g, 78%): Rf 0.50
(CH2Cl2/MeOH/H2O, 2:1:0.2); 1H NMR (250 MHz,
CD3OD) d 0.79 (m, 3H), 0.94 (s, 9H), 1.16 (m, 24H), 1.49
(m, 2H), 2.22 (m, 2H), 3.09 (s, 9H), 3.50 (m, 2H), 3.77 (d,
J¼4.7 Hz, 2H), 3.94 (m, 2H), 4.11 (m, 2H), 5.08 (m, 1H),
7.33 (m, 6H), 7.58 (m, 4H); 13C NMR (63 MHz, CD3OD) d
14.8, 20.4, 24.0, 26.3, 27.6, 30.5, 30.7, 30.8, 30.9, 31.1,
31.1, 33.4, 35.5, 54.9, 60.7 (d, Jcp¼5.0 Hz), 64.3, 65.3 (d,
Jcp¼5.3 Hz), 67.6, 75.0 (d, Jcp¼8.3 Hz), 129.2, 131.3,
134.6, 137.0, 175.1; FTIR (KBr, cm21) 3346, 2927, 2856,
1735, 1429, 1247, 1069, 969; FABHRMS [MþH]þ m/z
calcd for C40H69NO7PSi 734.4581, found 734.4581.
Acknowledgements
We are grateful to the KOSEF (R14-2002-015-01002-0) and
Ministry of Health & Welfare (01-PJ1-PG3-21500-0042)
for financial support of this research. Y.-A. Kim and M.-S.
Park are recipients of the graduate fellowship of Brain
Korea 21 program.
References
1. Shin, B. A.; Kim, Y. R.; Lee, I.-S.; Sung, C. K.; Hong, J.; Sim,
C. J.; Im, K. S.; Jung, J. H. J. Nat. Prod. 1999, 62, 1554.
2. Min, J.; Lee, Y.-J.; Kim, Y.-A.; Park, H.-S.; Han, S.-Y.; Jhon,
G.-J.; Choi, W. Biochim. Biophys. Acta 2001, 1531, 77.
3. Asaoka, Y.; Oka, M.; Yoshida, K.; Sasaki, Y.; Nishizuka, Y.
Proc. Natl Acad. Sci. USA 1992, 89, 6447.
3.1.9. 1-Lyso-2-palmitoyl-rac-glycero-3-phosphocholine
(1). To a solution of compound 10 (0.450 g, 0.610 mmol)
in DMSO/H2O (8:1, 6.1 mL) was added N-bromosuccini-
mide (0.330 g, 1.83 mmol) under dark. The mixture was
stirred for 72 h at room temperature and then lyophilized.
4. Yuan, Y.; Schoenwaelder, S. M.; Salem, H. H.; Jackson, S. P.
J. Biol. Chem. 1996, 271, 27090.
5. Yuan, Y.; Jackson, S. P.; Newnham, H. H.; Mitchell, C. A.;
Salem, H. H. Blood 1995, 86, 4166.
Chromatography
on
silica
gel
(CH2Cl2/MeOH,
5:1!1:3!0:1) gave 0.220 g (72%) of product 1 as a
white solid: Rf 0.21 (CH2Cl2/MeOH/2O, 2:1:0.2); 1H NMR
(250 MHz, CD3OD) d 0.89 (m, 3H), 1.28 (m, 24H), 1.60 (m,
2H), 2.35 (t, J¼7.4 Hz, 2H), 3.23 (s, 9H), 3.67 (m, 4H), 3.96
(m, 2H), 4.28 (m, 2H), 5.00 (m, 1H); 13C NMR (63 MHz,
CD3OD) d 14.8, 24.0, 26.3, 30.5, 30.8, 30.9, 31.1, 33.4,
35.4, 55.0, 60.7 (d, Jcp¼4.4 Hz), 61.5, 65.0 (d, Jcp¼5.0 Hz),
67.7, 74.9 (d, Jcp¼8.2 Hz), 175.1; FTIR (KBr, cm21) 3377,
2919, 2851, 1729, 1468, 1233, 967; FABHRMS [MþH]þ
m/z calcd for C24H51NO7P 496.3403, found 496.3405.
6. Wong, J. T.; Tran, K.; Pierce, G. N.; Chan, A. C.; Choy, P. C.
J. Biol. Chem. 1998, 273, 6830.
7. Durante, W.; Liao, L.; Peyton, K. J.; Schafer, A. I. J. Biol.
Chem. 1997, 272, 30154.
8. Pete, M. J.; Exton, J. H. Biochim. Biophys. Acta 1995, 1256,
367.
`
9. Thies, F.; Delachambre, M. C.; Bentejac, M.; Lagarde, M.;
Lecerf, J. J. Neurochem. 1992, 59, 1110.
10. Hirano, K.; Tanaka, A.; Yoshizumi, K.; Tanaka, T.; Satouchi,
K. J. Biochem. 1997, 122, 1160.